In Vitro Antibody-Dependent Enhancement of SARS-CoV-2 Infection Could Be Abolished by Adding Human IgG

Xun Wang, Minghui Li, Panpan Lu, Chen Li, Chaoyue Zhao, Xiaoyu Zhao, Rui Qiao, Yuchen Cui, Yanjia Chen, Jiayan Li, Guonan Cai, Pengfei WangPathogens 2023 · DOI

TL;DR

This study investigates Antibody-Dependent Enhancement (ADE) of SARS-CoV-2 infection in vitro, finding that both vaccine/convalescent sera and monoclonal antibodies can enhance viral entry into FcR-expressing cells. Crucially, this enhancement can be blocked by adding human IgG or by modifying the antibody's Fc region, suggesting that in vivo ADE might be less of a concern than in vitro findings suggest.

What Problem Does This Paper Address?

The development of vaccines and antibody therapies for SARS-CoV-2 has been a critical global effort. However, a significant safety concern with antibody-based interventions for viral diseases is the phenomenon of Antibody-Dependent Enhancement (ADE). ADE occurs when antibodies, instead of neutralizing a virus, paradoxically facilitate its entry into host cells, potentially leading to more severe disease. This has been observed with other viruses like Dengue and RSV, raising questions about the safety of SARS-CoV-2 vaccines and therapeutics. While some in vitro studies have suggested ADE for SARS-CoV-2, the extent to which this translates to real-world clinical scenarios remains unclear. This paper aims to explore the mechanisms behind SARS-CoV-2 ADE in vitro and investigate ways to mitigate it, providing insights into its potential clinical relevance.

Methods

The researchers employed a pseudovirus system to study SARS-CoV-2 infection. This involved creating viral particles that display the SARS-CoV-2 spike protein but contain a reporter gene (luciferase) for easy measurement of infection.

Key methods include:

  • Cell Culture: Various cell lines were used, including Vero-E6 cells (which express ACE2, the primary SARS-CoV-2 receptor) and Raji cells (a B cell line known to express Fc receptors, specifically FcyRIIB). THP-1 cells, a human monocytic cell line with lower FcR expression, were also used for comparison.
  • Pseudovirus Neutralization and ADE Assays:
    • Neutralization Assays: Performed on Vero-E6 cells to assess how well sera or antibodies block viral entry.
  • ADE Assays: Conducted on Raji cells to measure the enhancement of viral entry when antibodies are present, specifically looking for increased luciferase activity compared to virus-only controls.
  • Serum and Monoclonal Antibody Testing: Sera from vaccinated individuals, COVID-19 convalescents, and healthy donors were tested. Several approved SARS-CoV-2 monoclonal antibodies (mAbs) and mAb cocktails were also evaluated.
  • Blocking ADE: The researchers investigated two primary strategies to block ADE:
  • Addition of Human Serum/IgG: Testing the effect of adding normal human serum (NHS) or purified human IgG to the cell culture medium.
  • Antibody Fc Region Modification: Engineering mutations into the Fc region of mAbs to either abolish or enhance their binding to Fc receptors. Specifically, LALA mutations were introduced to abolish Fc-FcR interaction, and GASDALIE mutations were introduced to enhance it.
  • Quantitative and Statistical Analysis: Luciferase activity was measured, and statistical analyses were performed using GraphPad Prism to determine neutralization IC50 values and compare ADE infectivity fold changes.

Datasets

The study utilized the following:

  • Serum Samples: Sera were collected from 7 individuals who received three doses of an inactivated vaccine, 7 individuals who were infected with the BA.5 variant after vaccination, and 2 healthy individuals with no history of vaccination or infection (controls).
  • Monoclonal Antibodies: A panel of approved SARS-CoV-2 mAbs and mAb cocktails were used, including Brii-196, LY-CoV1404, COV2-2130 + COV2-2196, and REGN10987 + REGN10933.
  • SARS-CoV-2 Pseudoviruses: Both wild-type (D614G) and Omicron XBB.1.5 variant pseudoviruses were constructed and used.

No new benchmarks were introduced; the study focused on evaluating existing sera and mAbs in established in vitro assay systems.

Key Insights and Ideas

  • ADE is FcR-Dependent: The study strongly suggests that in vitro ADE of SARS-CoV-2 is critically dependent on the expression of Fc receptors (FcRs) on the target cells. Raji cells, with high FcyRIIB expression, showed ADE, while THP-1 cells with lower expression did not.
  • Human IgG is a Potent Blocker of In Vitro ADE: The addition of human serum or purified human IgG effectively abolished the ADE phenomenon observed in vitro. This implies that the natural presence of IgG in the body could act as a buffer against ADE.
  • Fc Region Engineering Can Abolish ADE: Modifying the Fc region of mAbs, specifically by introducing mutations that prevent Fc-FcR binding (LALA mutations), completely eliminated ADE activity. This provides a direct link between Fc-FcR interaction and ADE.
  • In Vitro ADE May Not Directly Predict In Vivo Risk: The most significant takeaway is the caution that in vitro ADE findings might not accurately reflect the situation in vivo. The ability of human IgG to block ADE in vitro suggests that the complex in vivo environment, with its abundant IgG, might significantly mitigate ADE risks associated with vaccines and therapies.
  • Variant-Specific ADE: The study noted that LY-CoV1404 showed ADE with the WT virus but not with the XBB.1.5 variant, highlighting that ADE susceptibility can be influenced by both antibody binding and viral variant characteristics.

Key Results

  • Sera and mAbs induce ADE: Both vaccination/convalescent sera and approved SARS-CoV-2 mAbs were shown to enhance pseudoviral infection of Raji cells (FcR-expressing B cells) in vitro.
  • LY-CoV1404 showed strongest ADE: Among the tested mAbs, LY-CoV1404 exhibited the most pronounced ADE activity.
  • ADE abolished by 5-10% NHS: The addition of 5-10% normal human serum (NHS) significantly reduced, and in some cases completely abolished, mAb-induced ADE.
  • ADE abolished by purified human IgG: Purified human IgG (100 µg/mL) effectively reduced ADE activities of tested mAbs.
  • LALA mutations abolish ADE: mAbs with LALA mutations in their Fc region showed no ADE activity.
  • GASDALIE mutations enhance ADE: Conversely, mAbs with GASDALIE mutations (enhancing Fc-FcR binding) showed increased ADE activity.
  • No ADE with XBB.1.5 for LY-CoV1404: LY-CoV1404 did not induce ADE with the XBB.1.5 variant, likely due to reduced binding.

Limitations and Future Work

Limitations:

  • In Vitro vs. In Vivo: The authors explicitly state that ADE activity observed in vitro may not necessarily reflect the situation in vivo. The study relies on cell culture models, which lack the complexity of a living organism.
  • Limited Donor Numbers: The study acknowledges a limitation in the number of donors, particularly the inclusion of only two healthy donors for control sera.
  • FcR Expression Variability: While Raji cells showed ADE, THP-1 cells did not, indicating that ADE is highly dependent on the specific FcR expression levels of the target cells, which can vary.

Future Work:

  • Animal and Clinical Data: The authors emphasize the critical need to include animal and clinical data for a comprehensive ADE evaluation, moving beyond in vitro findings.
  • Understanding In Vivo Buffering: Further research is needed to fully understand how the presence of human IgG in circulation acts as a natural buffer against ADE.
  • Variant Impact: Continued monitoring of new SARS-CoV-2 variants and their potential impact on ADE is essential for vaccine and therapy safety.
  • Real-World Data: The paper points to real-world data involving billions of vaccinated individuals, which supports the notion that ADE is not a widespread issue in practice, but ongoing vigilance is necessary.
  • Comprehensive Evaluation: The study concludes that ADE is a complex process requiring comprehensive evaluation of preclinical data, clinical trials, and ongoing monitoring to fully understand its role in human COVID-19 pathology.

Summary updated

Abstract

Evidence of antibody-dependent enhancement (ADE) of other viruses has raised concerns about the safety of SARS-CoV-2 vaccines and antibody therapeutics. In vitro studies have shown ADE of SARS-CoV-2 infection. In this study, we also found that vaccination/convalescent sera and some approved monoclonal antibodies can enhance SARS-CoV-2 infection of FcR-expressing B cells in vitro. However, the enhancement of SARS-CoV-2 infection can be prevented by blocking Fc-FcR interaction through the addition of human serum/IgG or the introduction of mutations in the Fc portion of the antibody. It should be noted that ADE activity observed on FcR-expressing cells in vitro may not necessarily reflect the situation in vivo; therefore, animal and clinical data should be included for ADE evaluation.
BibTeX
@inproceedings{wang2023vitro,
  author = {Xun Wang and Minghui Li and Panpan Lu and Chen Li and Chaoyue Zhao and Xiaoyu Zhao and Rui Qiao and Yuchen Cui and Yanjia Chen and Jiayan Li and Guonan Cai and Pengfei Wang},
  title = {{In Vitro Antibody-Dependent Enhancement of SARS-CoV-2 Infection Could Be Abolished by Adding Human IgG}},
  booktitle = {Pathogens},
  year = {2023},
  doi = {10.3390/pathogens12091108},
}
Figure